nifedipine has been researched along with Hyperlipidemias in 13 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Hyperlipidemias: Conditions with excess LIPIDS in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs." | 9.08 | Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis. ( Furue, M; Koga, T; Nakayama, J, 1998) |
| "The improvement in postprandial lipidemia by nifedipine may add to its anti-atherogenic effects in hypertensive patients." | 6.82 | Nifedipine Treatment for Hypertension is Associated with Enhanced Lipolytic Activity and Accelerated Clearance of Postprandial Lipemia. ( Charach, G; Grosskopf, I; Harats, D; Kamari, Y; Shaish, A, 2016) |
| "Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs." | 5.08 | Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis. ( Furue, M; Koga, T; Nakayama, J, 1998) |
| "The effect of nicardipine on experimental hyperlipemia induced by a 1% cholesterol diet in spontaneously hypertensive rats (SHR) was investigated by the change of hemodynamics and the determination of lipid contents of the serum, liver, heart and aorta." | 3.67 | [Effect of nicardipine on cholesterol-fed S.H.R]. ( Kawashima, I; Nakayama, S; Ohba, T; Sakamoto, K; Tonooka, M; Yasuhara, H, 1985) |
| "The improvement in postprandial lipidemia by nifedipine may add to its anti-atherogenic effects in hypertensive patients." | 2.82 | Nifedipine Treatment for Hypertension is Associated with Enhanced Lipolytic Activity and Accelerated Clearance of Postprandial Lipemia. ( Charach, G; Grosskopf, I; Harats, D; Kamari, Y; Shaish, A, 2016) |
| "Treatment with enalapril was associated with a greater reduction in albuminuria than with nifedipine in the entire patient group, and especially in those with microalbuminuria." | 2.69 | Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. ( Chan, JC; Cheung, MY; Cheung, RC; Cockram, CS; Critchley, JA; Ko, GT; Leung, DH; Nicholls, MG; So, WY; Swaminathan, R, 2000) |
| " doses, respectively, thereby increasing AUC0-infinity, Cmax and half-life." | 1.30 | Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. ( Eliot, LA; Foster, RT; Jamali, F, 1999) |
| "Atorvastatin treatment significantly reduced this prolongation to 46%." | 1.30 | Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats. ( Eliot, LA; Jamali, F, 1999) |
| "Nifedipine treatment significantly prevented STZ-induced increase in cholesterol and triglyceride levels." | 1.29 | Effects of chronic nifedipine treatment on streptozotocin-induced diabetic rats. ( Bangaru, RA; Gandhi, TP; Goyal, RK; Satia, MC; Shah, TS, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grosskopf, I | 1 |
| Shaish, A | 1 |
| Charach, G | 1 |
| Harats, D | 1 |
| Kamari, Y | 1 |
| Kobayashi, M | 1 |
| Moriya, K | 1 |
| Eguchi, Y | 1 |
| Sugimoto, A | 1 |
| Ito, S | 1 |
| Ishikawa, M | 1 |
| Shah, TS | 1 |
| Satia, MC | 1 |
| Gandhi, TP | 1 |
| Bangaru, RA | 1 |
| Goyal, RK | 1 |
| Ariad, S | 1 |
| Hechtlinger, V | 1 |
| Nakayama, J | 1 |
| Koga, T | 1 |
| Furue, M | 1 |
| Eliot, LA | 2 |
| Foster, RT | 1 |
| Jamali, F | 2 |
| Chan, JC | 1 |
| Ko, GT | 1 |
| Leung, DH | 1 |
| Cheung, RC | 1 |
| Cheung, MY | 1 |
| So, WY | 1 |
| Swaminathan, R | 1 |
| Nicholls, MG | 1 |
| Critchley, JA | 1 |
| Cockram, CS | 1 |
| Duan, HW | 1 |
| Zhang, YZ | 1 |
| Yan, XF | 1 |
| Ishikawa, Y | 2 |
| Watanabe, N | 2 |
| Okamoto, R | 2 |
| Watanabe, Y | 2 |
| Fukuzaki, H | 2 |
| Ohba, T | 1 |
| Tonooka, M | 1 |
| Kawashima, I | 1 |
| Nakayama, S | 1 |
| Yasuhara, H | 1 |
| Sakamoto, K | 1 |
3 trials available for nifedipine and Hyperlipidemias
| Article | Year |
|---|---|
Nifedipine Treatment for Hypertension is Associated with Enhanced Lipolytic Activity and Accelerated Clearance of Postprandial Lipemia.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Female; Humans; Hyperlipidemias; Hypertension; | 2016 |
Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.
Topics: Adult; Aged; Blood Pressure Determination; Calcium Channel Blockers; Cyclosporine; Delayed-Action Pr | 1998 |
Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Diabetes Mellitus, Type 2; | 2000 |
10 other studies available for nifedipine and Hyperlipidemias
| Article | Year |
|---|---|
[Effect of EG-1088, EG-626 and nifedipine on vascular lesions associated with hypertension and hyperlipidemia in stroke-prone spontaneously hypertensive rats (SHR-SP)].
Topics: Animals; Aorta; Arteries; Basilar Artery; Blood Pressure; Cerebral Arteries; Hyperlipidemias; Hypert | 1984 |
Effects of chronic nifedipine treatment on streptozotocin-induced diabetic rats.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Bradycardia; | 1995 |
Bezafibrate-induced neutropenia.
Topics: Bezafibrate; Dyspnea; Female; Flushing; Humans; Hyperlipidemias; Hypertension; Leukocyte Count; Midd | 1993 |
Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat.
Topics: Animals; Area Under Curve; Blood Proteins; Calcium Channel Blockers; Hyperlipidemias; Male; Nifedipi | 1999 |
Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholester | 1999 |
[Effect of high density lipoprotein (HDL) on the clearance of intracellular lipids with special reference to the co-effect of nifedipine].
Topics: Animals; Biological Transport, Active; Cells, Cultured; Cholesterol; Drug Synergism; Foam Cells; Hyp | 1992 |
[Effects of nifedipine and Paeonia lactiflora on plasma TXB2 and 6-Keto-PGF1 alpha in cholesterol-fed rabbits].
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Cholesterol, Dietary; Drugs, Chinese Herbal; Hyperlipidemias; | 1990 |
Nifedipine-suppressed atherosclerosis in cholesterol-fed rabbits but not in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Arteriosclerosis; Cholesterol, Dietary; Hyperlipidemias; Male; Nifedipine; Rabbits | 1987 |
Nifedipine suppressed atherosclerosis in cholesterol-fed rabbits but not in Watanabe heritable hyperlipidemic rabbits.
Topics: Administration, Oral; Animals; Aorta; Arteriosclerosis; Cholesterol, Dietary; Female; Hyperlipidemia | 1987 |
[Effect of nicardipine on cholesterol-fed S.H.R].
Topics: Animals; Aorta; Arteriosclerosis; Body Weight; Heart Rate; Hyperlipidemias; Hypertension; Lipids; Li | 1985 |